Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Intellectual Disability01:29

Intellectual Disability

796
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
796
Learning Disabilities01:25

Learning Disabilities

639
Learning disabilities are cognitive disorders caused by neurological impairments that affect cognitive functions like language and reading, without indicating overall intellectual or developmental challenges. These disabilities differ from global intellectual or developmental disabilities as they are limited to distinct cognitive functions. Common learning disabilities include dysgraphia, dyslexia, and dyscalculia, each of which impacts unique aspects of learning.
Dyslexia
Dyslexia is a...
639
Tumor Progression02:07

Tumor Progression

7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Translesion DNA Polymerases02:10

Translesion DNA Polymerases

11.3K
Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
11.3K
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

41.0K
Overview
41.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The AI-informed patient.

British dental journal·2026
Same author

Parallel Age-Related Cochlear Neural Degeneration and Cortical Gain Adaptation in Normal-Hearing Humans.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2026
Same author

Are exercise booster sessions effective at preserving exercise-induced effects in people with multiple sclerosis? A randomised controlled trial: results from the MSBOOST trial.

Journal of science and medicine in sport·2026
Same author

Corrigendum to 'Response to letter to the editor (JOTNS-D-25-02717 by Dr. Nie Lei)' [The Journal of the Neurological Sciences 2025 Volume 479 123752].

Journal of the neurological sciences·2025
Same author

Significance and stability of cerebrospinal fluid oligoclonal band patterns in multiple sclerosis.

Multiple sclerosis and related disorders·2025
Same author

Response to letter to the editor (JOTNS-D-25-02717 by Dr. Nie Lei).

Journal of the neurological sciences·2025
Same journal

Patterns of psychological resilience and social avoidance among the patients of Neuromyelitis Optica Spectrum Disease: a latent profile analysis.

Multiple sclerosis and related disorders·2026
Same journal

Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.

Multiple sclerosis and related disorders·2026
Same journal

Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same journal

Comparative immunopathology and clinical features of MOGAD and AQP4-IgG NMOSD in children: A scoping review.

Multiple sclerosis and related disorders·2026
Same journal

Self-perception of speech impairment in MS: Associations with dysarthria severity and speech measures.

Multiple sclerosis and related disorders·2026
Same journal

Taking progressive biology seriously in the time of B-cells and BTK.

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Feb 15, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K

Disability in progressive MS is associated with T2 lesion changes.

C Ammitzbøll1, T B Dyrby2, M Lyksborg3

  • 1Danish Multiple Sclerosis Center, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Multiple Sclerosis and Related Disorders
|January 12, 2018
PubMed
Summary
This summary is machine-generated.

Clinical disability in progressive multiple sclerosis (MS) correlates with lesion volume and microstructure. Advanced MRI measures like magnetisation transfer ratio (MTR) and mean diffusivity (MD) in lesions are key indicators.

Keywords:
Diffusion tensor imagingExpanded disability status scaleMagnetic resonance imagingMagnetisation transfer ratioMultiple sclerosisMultiple sclerosis functional composite

More Related Videos

Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration
05:30

Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration

Published on: May 19, 2023

1.9K
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K

Related Experiment Videos

Last Updated: Feb 15, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K
Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration
05:30

Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration

Published on: May 19, 2023

1.9K
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomedical Engineering

Background:

  • Progressive multiple sclerosis (MS) presents diffuse brain changes on MRI, challenging its use as a diagnostic and prognostic tool.
  • Understanding the link between MRI metrics and clinical disability in progressive MS is crucial for patient management.

Purpose of the Study:

  • To investigate the relationship between clinical disability assessments and various MRI measures in patients with progressive MS.

Main Methods:

  • Cross-sectional study of 93 progressive MS patients from phase 2 clinical trials.
  • Baseline 3T MRI scans analyzed for T2 lesion volume, magnetisation transfer ratio (MTR), fractional anisotropy (FA), and mean diffusivity (MD) in lesions, normal-appearing white matter (NAWM), and cortical grey matter.
  • Clinical disability assessed using the Expanded Disability Status Scale (EDSS) and MS functional composite.

Main Results:

  • T2 lesion volume significantly correlated with all clinical disability measures.
  • Mean diffusivity (MD) and magnetisation transfer ratio (MTR) in T2 lesions showed significant relationships with disability.
  • Lower fractional anisotropy (FA) in normal-appearing white matter (NAWM) was associated with poorer hand function.
  • Multivariable analysis confirmed independent correlations between increasing clinical disability, T2 lesion volumes, and MTR in T2 lesions.

Conclusions:

  • Clinical disability in progressive MS is significantly associated with lesion volume and tissue microstructure.
  • MRI measures, including lesion load and microstructural integrity (MTR, MD, FA), offer valuable insights into progressive MS.
  • These findings highlight the potential of advanced MRI techniques for assessing and monitoring progressive MS.